STOCK TITAN

ParkerVision (PRKR) registers 13.34M shares; CEO/CFO options extended

(Neutral)
(Neutral)
Form Type
424B3

Rhea-AI Filing Summary

ParkerVision, Inc. files a Prospectus Supplement registering 13,342,953 shares of Common Stock for resale by selling stockholders under its shelf prospectus. The supplement states the company will receive no proceeds from resales; cash proceeds up to $2,833,756 are possible if outstanding warrants are exercised.

The filing also attaches a Form 8-K disclosing that the Compensation Committee extended expiration dates for previously issued, fully vested nonqualified stock options for CEO Jeffrey Parker (2,660,000 options) and CFO Cynthia French (870,550 options) from August 7, 2026 to August 7, 2029. The exercise price remains $0.171 per share. The company expects a one-time non-cash share-based compensation charge of approximately $360,000.

Positive

  • None.

Negative

  • None.

Insights

Option extensions preserve previously granted economic terms; expect a one-time non-cash charge.

Extending the expiration dates of fully vested, nonqualified options (2,660,000 and 870,550 options) keeps the original exercise price of $0.171 while lengthening the term to August 7, 2029. The change is described as the sole modification, with no new securities issued.

The company expects to record a one-time non-cash $360,000 share-based compensation charge; the accounting impact is discrete and timing is tied to the modification date of April 22, 2026. Subsequent filings will show the actual charge in reported results.

Prospectus Supplement registers resale capacity and confirms limited issuer proceeds only from warrant exercises.

The supplement registers 13,342,953 shares for resale by selling stockholders and states the issuer will not receive proceeds from those resales. It discloses potential cash inflows of up to $2,833,756 if warrants are exercised for cash.

Use of any warrant exercise proceeds is stated as for general working capital, including litigation expenses. The supplement attaches the referenced Form 8-K dated April 22, 2026.

Registered shares 13,342,953 shares Prospectus Supplement registration of resale capacity
Potential warrant proceeds $2,833,756 Aggregate gross proceeds if Warrants exercised for cash
CEO options 2,660,000 options Options awarded August 7, 2019; expiration extended to August 7, 2029
CFO options 870,550 options Options awarded August 7, 2019; expiration extended to August 7, 2029
Exercise price $0.171 per share Unchanged exercise price for the modified options
One-time charge $360,000 Expected one-time non-cash share-based compensation charge from modification
Prospectus Supplement regulatory
"relates to the prospectus dated April 26, 2021, as amended"
A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.
resale by selling stockholders financial
"permits the resale by the selling stockholders listed in the Prospectus"
nonqualified stock options financial
"modified certain outstanding nonqualified stock options held by its Chief Executive Officer"
A nonqualified stock option is a company-issued right that lets an employee or contractor buy shares later at a preset price, like a coupon to purchase stock regardless of the market price. It matters to investors because when the option is used the recipient owes ordinary-income tax on the difference between market and preset price, which affects the holder’s financial decisions and can change the company’s share count and reported expenses.
share-based compensation charge accounting
"expects to record a one-time non-cash share-based compensation charge"
warrants financial
"shares of Common Stock underlying warrants issued pursuant to securities purchase agreements"
Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.
Offering Type resale/secondary
Use of Proceeds Proceeds from warrant exercises, if any, expected for general working capital, including payment of litigation expenses

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What does ParkerVision's prospectus supplement (PRKR) register?

It registers 13,342,953 shares of Common Stock for resale by selling stockholders. The supplement attaches an 8-K and updates the previously filed prospectus.

Will ParkerVision receive proceeds from the registered resales?

No; the company states it will not receive proceeds from resales by the selling stockholders. Cash proceeds apply only if warrants are exercised for cash.

How much could ParkerVision receive if warrants are exercised?

If the outstanding warrants are exercised for cash, the company could receive up to $2,833,756 in gross proceeds to be used for general working capital, including litigation expenses.

What option changes did ParkerVision disclose on Form 8-K?

The Compensation Committee extended expirations for options awarded on August 7, 2019: 2,660,000 to the CEO and 870,550 to the CFO, moving maturities to August 7, 2029 while keeping the $0.171 exercise price.

Will the option modifications create an accounting charge?

Yes; the company expects to record a one-time non-cash share-based compensation charge of approximately $360,000 related to the option extensions in connection with the modification.

Filed pursuant to Rule 424(b)(3)

Registration No. 333-255217

 

PROSPECTUS SUPPLEMENT No. 58

(to Prospectus dated April 26, 2021)

 

PARKERVISION, INC.

13,342,953 Shares of Common Stock

 

This Prospectus Supplement relates to the prospectus dated April 26, 2021, as amended and supplemented from time to time (the “Prospectus”), which permits the resale by the selling stockholders listed in the Prospectus of up to 13,342,953 shares of our common stock, par value $0.01 per share (“Common Stock”) consisting of (i) an aggregate of 7,962,722 shares of Common Stock issued pursuant to securities purchase agreements dated October 5, 2020, November 17, 2020, December 11, 2020, December 21, 2020 and January 5, 2021, (ii) an aggregate of 3,230,942 shares of Common Stock and 1,619,289 shares of Common Stock underlying warrants (“Warrants”) issued pursuant to securities purchase agreements dated March 29, 2021, (iii) 530,000 shares of Common Stock issued as payment for services.

 

We will not receive proceeds from the sale of the shares of Common Stock by the selling stockholders. To the extent the Warrants are exercised for cash, we will receive up to an aggregate of $2,833,756 in gross proceeds.  We expect to use the proceeds received from the exercise of the Warrants, if any, for general working capital purposes, including payment of litigation expenses.

 

This Prospectus Supplement is being filed to update and supplement the information previously included in the Prospectus with the information contained in our Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on April 27, 2026.  Accordingly, we have attached the 8-K to this prospectus supplement.  You should read this prospectus supplement together with the prospectus, which is to be delivered with this prospectus supplement.

 

Any statement contained in the Prospectus shall be deemed to be modified or superseded to the extent that information in this Prospectus Supplement modifies or supersedes such statement.  Any statement that is modified or superseded shall not be deemed to constitute a part of the Prospectus except as modified or superseded by this Prospectus Supplement. 

 

This Prospectus Supplement should be read in conjunction with, and may not be delivered or utilized without, the Prospectus.

 

Our Common Stock is listed on the OTCQB Venture Capital Market under the ticker symbol “PRKR.”

 

Investing in our securities involves a high degree of risk. See Risk Factors beginning on page 6 of the Prospectus for a discussion of information that should be considered in connection with an investment in our securities.

 

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved these securities or determined whether this Prospectus or Prospectus Supplement is truthful or complete. Any representation to the contrary is a criminal offense.

 

The date of this Prospectus Supplement is April 27, 2026.

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

______________

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported):April 22, 2026

 

PARKERVISION, INC.

(Exact Name of Registrant as Specified in Charter)

     

Florida

000-22904

59-2971472

(State or Other Jurisdiction of Incorporation)

(Commission File Number)

(IRS Employer Identification No.)

 

   

4446-1A Hendricks Avenue Suite 354, Jacksonville, Florida

32207

(Address of Principal Executive Offices)

(Zip Code)

 

(904) 732-6100

(Registrant’s Telephone Number, Including Area Code)

 

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

   

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

   

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

   

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e 4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class

Trading Symbol

Name of Each Exchange on Which Registered

None

 

 

 

 

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter.

 

Emerging growth company   ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐

 

 

 

 

Item 5.02(e) Compensatory Arrangements of Certain Officers

 

On April 22, 2026, the Compensation Committee of the Board of Directors (“Committee”) of ParkerVision, Inc. (the “Company”), approved the modification of certain outstanding nonqualified stock options held by its Chief Executive Officer, Jeffrey Parker, and its Chief Financial Officer, Cynthia French, in order to extend the expiration date of the options from August 7, 2026 to August 7, 2029 to preserve the intended long-term incentive value of the awards.

 

The modified options include 2,660,000 options awarded to Mr. Parker and 870,550 options awarded to Ms. French on August 7, 2019, with an exercise price of $0.171 per share and an original term of seven years. The options were fully vested as of the modification date and the Company expects to record a one-time non-cash share-based compensation charge of approximately $360,000 in connection with the modification of these awards.

 

The extension of the expiration date is the only modification made to these awards, and no changes were made to the exercise price, the number of shares subject to the awards, vesting status or any other terms of the awards. No additional securities were issued in connection with the modification.

 

 

 Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits:

 

Exhibit

Description

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

     

Dated: April 27, 2026

   
   

PARKERVISION, INC.

     
   

By /s/ Cynthia French

   

Cynthia French

   

Chief Financial Officer